Novo Nordisk to Pay Up to $2 Billion to License Chinese Company's Weight-Loss Drug -- Barrons.com

Dow Jones

03-24

By Mackenzie Tatananni

Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to Novo's Ozempic.

The Danish pharma giant said it would pay $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the rights to UBT251, a drug in early-stage clinical development for the treatment of type 2 diabetes, obesity, and other diseases.

UBT251 is what's known as a "triple agonist." It binds to the body's receptors for GLP-1, GIP, and glucagon, mimicking the effects of the hormones to manage blood sugar levels and promote insulin secretion.

United Biotechnology, a subsidiary wholly owned by United Laboratories International, will retain the rights for UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan. Novo Nordisk will be granted exclusive rights to develop, manufacture, and commercialize the drug elsewhere.

Novo Nordisk is currently a leader in the U.S. market for GLP-1 drugs. The company is the maker of Ozempic and Wegovy, two differently branded versions of the same semaglutide drug that are approved for diabetes treatment and weight loss, respectively.

U.S.-listed shares of Novo Nordisk fell 2.2% to $75.20 in premarket trading Monday. Futures tracking the S&P 500 were up 1.1%.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

March 24, 2025 07:42 ET (11:42 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2521674404"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521674404\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2521674404?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521674404","market":"sg","top_or_hot":-1,"title":"Novo Nordisk to Pay Up to $2 Billion to License Chinese Company's Weight-Loss Drug -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Mackenzie Tatananni \n</p>\n<p>\n  Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to Novo's Ozempic. \n</p>\n<p>\n     The Danish pharma giant said it would pay $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the rights to UBT251, a drug in early-stage clinical development for the treatment of type 2 diabetes, obesity, and other diseases. \n</p>\n<p>\n     UBT251 is what's known as a \"triple agonist.\" It binds to the body's receptors for GLP-1, GIP, and glucagon, mimicking the effects of the hormones to manage blood sugar levels and promote insulin secretion. \n</p>\n<p>\n     United Biotechnology, a subsidiary wholly owned by United Laboratories International, will retain the rights for UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan. Novo Nordisk will be granted exclusive rights to develop, manufacture, and commercialize the drug elsewhere. \n</p>\n<p>\n     Novo Nordisk is currently a leader in the U.S. market for GLP-1 drugs. The company is the maker of Ozempic and Wegovy, two differently branded versions of the same semaglutide drug that are approved for diabetes treatment and weight loss, respectively. \n</p>\n<p>\n     U.S.-listed shares of Novo Nordisk fell 2.2% to $75.20 in premarket trading Monday. Futures tracking the S&amp;P 500 were up 1.1%. \n</p>\n<p>\n     Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 07:42 ET (11:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk to Pay Up to $2 Billion to License Chinese Company's Weight-Loss Drug -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk to Pay Up to $2 Billion to License Chinese Company's Weight-Loss Drug -- Barrons.com\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-24 19:42</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Mackenzie Tatananni \n</p>\n<p>\n  Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to Novo's Ozempic. \n</p>\n<p>\n     The Danish pharma giant said it would pay $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the rights to UBT251, a drug in early-stage clinical development for the treatment of type 2 diabetes, obesity, and other diseases. \n</p>\n<p>\n     UBT251 is what's known as a \"triple agonist.\" It binds to the body's receptors for GLP-1, GIP, and glucagon, mimicking the effects of the hormones to manage blood sugar levels and promote insulin secretion. \n</p>\n<p>\n     United Biotechnology, a subsidiary wholly owned by United Laboratories International, will retain the rights for UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan. Novo Nordisk will be granted exclusive rights to develop, manufacture, and commercialize the drug elsewhere. \n</p>\n<p>\n     Novo Nordisk is currently a leader in the U.S. market for GLP-1 drugs. The company is the maker of Ozempic and Wegovy, two differently branded versions of the same semaglutide drug that are approved for diabetes treatment and weight loss, respectively. \n</p>\n<p>\n     U.S.-listed shares of Novo Nordisk fell 2.2% to $75.20 in premarket trading Monday. Futures tracking the S&amp;P 500 were up 1.1%. \n</p>\n<p>\n     Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 07:42 ET (11:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2521674404","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521674404","pubTimestamp":1742816520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to Novo's Ozempic.The Danish pharma giant said it would pay $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the rights to UBT251, a drug in early-stage clinical development for the treatment of type 2 diabetes, obesity, and other diseases.UBT251 is what's known as a \"triple agonist.\" It binds to the body's receptors for GLP-1, GIP, and glucagon, mimicking the effects of the hormones to manage blood sugar levels and promote insulin secretion.United Biotechnology, a subsidiary wholly owned by United Laboratories International, will retain the rights for UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan. Novo Nordisk will be granted exclusive rights to develop, manufacture, and commercialize the drug elsewhere.Novo Nordisk is currently a leader in the U.S. market for GLP-1 drugs. The company is the maker ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"诺和诺德将支付高达20亿美元获得中国公司减肥药的许可--Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"By Mackenzie Tatananni \n\n\n  Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to Novo's Ozempic. \n\n\n     The Danish pharma giant said it would pay $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the rights to UBT251, a drug in early-stage clinical development for the treatment of type 2 diabetes, obesity, and other diseases. \n\n\n     UBT251 is what's known as a \"triple agonist.\" It binds to the body's receptors for GLP-1, GIP, and glucagon, mimicking the effects of the hormones to manage blood sugar levels and promote insulin secretion. \n\n\n     United Biotechnology, a subsidiary wholly owned by United Laboratories International, will retain the rights for UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan. Novo Nordisk will be granted exclusive rights to develop, manufacture, and commercialize the drug elsewhere. \n\n\n     Novo Nordisk is currently a leader in the U.S. market for GLP-1 drugs. The company is the maker of Ozempic and Wegovy, two differently branded versions of the same semaglutide drug that are approved for diabetes treatment and weight loss, respectively. \n\n\n     U.S.-listed shares of Novo Nordisk fell 2.2% to $75.20 in premarket trading Monday. Futures tracking the S&P 500 were up 1.1%. \n\n\n     Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com \n\n\n     This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 07:42 ET (11:42 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}